In This Article:
Toronto, Ontario--(Newsfile Corp. - April 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the successful signing of a new customer, resulting in an initial purchase order for 200 units of its flagship Venowave VW5 product, ("Venowave").
This purchase order underscores the continued demand for Venowave and the strength of the Company's product offering despite a challenging global business environment. The new customer, a key distributor within the Durable Medical Equipment sector, will be introducing Venowave to their established customer base.
Early indications following this initial order and a successful market launch over the next two months suggest the potential for significant follow-on orders of Venowave. Therma Bright is optimistic about the prospects of this new partnership and the opportunity to further expand the reach of its innovative medical device.
Rob Fia, CEO, commented: "This initial order is a testament to the value proposition of Venowave and the dedication of our team. We are excited to partner with this new distributor and look forward to the potential for substantial growth in this channel."
Therma Bright remains committed to navigating the evolving global trade environment and will continue to explore all available options to ensure the consistent and cost-effective delivery of its products to the market.
Further updates regarding the progress of this new business relationship and subsequent order volumes will be provided as they become available.
Therma Bright also announces that further to its press release of January 9, 2025, it has now issued 2,000,000 common shares at a deemed price of $0.05 per share to settle aggregate debt of $100,000. All shares issued in relation to this debt settlement are subject to a hold period expiring August 24, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
The Company also announces that it has negotiated a debt settlement with an arm's length creditor pursuant to which it proposes to settle aggregate debt of $24,000 in consideration for which it will issue an aggregate of 676,000 common shares at a deemed price of $0.0355 per share, subject to acceptance by the TSX Venture Exchange.
Venowave, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is a compact, battery-operated peristaltic pump designed to enhance vascular and lymphatic flow in the lower limbs. When strapped below the knee, the device generates a wave-form motion that compresses the calf, promoting upward displacement of venous and lymphatic fluid. Powered by a single rechargeable 1.5V NiMH AA battery, the FDA-designated Durable Medical Equipment (DME) device allows users to receive treatment while staying active. The Venowave is built for durability and supports repeated use across multiple patients.